Role of FDG PET in the management of childhood lymphomas - case proven or is the jury still out?

European Journal of Cancer

Volumn 44, Issue 5, 2008, Pages 663-673

  Shankar, Ananth ^a   Fiumara, Frank ^b   Pinkerton, Ross ^c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Childhood lymphomas; FDG PET; Response assessment; Staging; Surveillance

Indexed keywords

DOXORUBICIN; ETOPOSIDE; GALLIUM; PREDNISOLONE; VINCRISTINE;

ARTICLE; CANCER PATIENT; CANCER STAGING; CHILDHOOD CANCER; DOSIMETRY; HODGKIN DISEASE; HUMAN; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PATIENT ASSESSMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTIGRAPHY; TREATMENT RESPONSE;

CHILD; FALSE POSITIVE REACTIONS; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HUMANS; LYMPHOMA; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 40849141827     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.02.005     Document Type: Article

References (81)

1. Pauwels E.K., Ribeiro M.J., Stoot J.H., McCready V.R., Bourguignon M., and Mazière B. FDG accumulation and tumor biology. Nucl Med Biol 25 (1998) 317-322
2. Jerusalem G., Beguin Y., Fassotte M.F., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94 (1999) 429-433
3. Kostakoglu L., Agress Jr. H., and Goldsmith S.J. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 23 (2003) 315-340
4. Canellos G.P. Residual mass in lymphoma may not be residual disease. J Clin Oncol 6 (1988) 931-933
5. Gdeedo A., Van Schil P., Corthouts B., Van Mieghem F., Van Meerbeeck J., and Van Marck E. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J 10 (1997) 1547-1551
6. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 (1999) 1244-1253 [Erratum in J Clin Oncol. 2000, 18, 2351]
7. Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., and Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31 (1971) 1860-1861
8. Murphy S.B. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphoma: dissimilarities from lymphomas in adults. Semin Oncol 7 (1980) 332-339
9. Bekerman C., Hoffer P.B., and Bitran J.D. The role of gallium-67 in the clinical evaluation of cancer. Semin Nucl Med 14 (1984) 296-323
10. Gallamini A., Biggi A., Fruttero A., et al. Revisiting the prognostic role of gallium scintigraphy in low-grade non-Hodgkin's lymphoma. Eur J Nucl Med 24 (1997) 1499-1506
11. Kostakoglu L., and Goldsmith S.J. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?. Eur J Nucl Med 27 (2000) 1564-1578
12. Kostakoglu L., Leonard J.P., Kuji I., Coleman M., Vallabhajosula S., and Goldsmith S.J. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 94 (2002) 879-888
13. Rini J.N., Núñez R., Nichols K., et al. Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin's disease. Pediatr Radiol 35 (2005) 169-178
14. Bar-Shalom R., Yefremov N., Haim N., et al. Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma: comparative study. Radiology 227 (2003) 353-360
15. Bangerter M., Moog F., Buchmann I., et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 9 (1998) 1117-1122
16. Moog F., Bangerter M., Diederichs C.G., et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206 (1998) 475-481
17. Partridge S., Timothy A., O'Doherty M.J., Hain S.F., Rankin S., and Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 11 (2000) 1273-1279
18. Sasaki M., Kuwabara Y., Koga H., et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 16 (2002) 337-345
19. Munker R., Glass J., Griffeth L.K., et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 15 (2004) 1699-1704
20. Naumann R., Beuthien-Baumann B., Reiss A., et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 90 (2004) 620-625
21. la Fougère C., Hundt W., Bröckel N., et al. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 33 (2006) 1417-1425
22. Hutchings M., Loft A., Hansen M., et al. Positron emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 91 (2006) 482-489
23. Tsukamoto N., Kojima M., Hasegawa M., et al. The usefulness of (18) F-fluorodeoxyglucose positron emission tomography ((18) F-FDG-PET) and a comparison of (18) F-FDG-pet with (67) gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 110 (2007) 652-659
24. Rigacci L., Vitolo U., Nassi L., et al. On behalf of Intergruppo Italiano Linfomi. Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 86 (2007) 897-903
25. Wegner E.A., Barrington S.F., Kingston J.E., et al. The impact of PET scanning on management of paediatric oncology patients. Eur J Nucl Med Mol Imaging 32 (2005) 23-30
26. Montravers F., McNamara D., Landman-Parker J., et al. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 29 (2002) 1155-1165
27. Hermann S., Wormanns D., Pixberg M., et al. Staging in childhood lymphoma: differences between FDG-PET and CT. Nuklearmedizin 44 (2005) 1-7
28. Depas G., De Barsy C., Jerusalem G., et al. 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 32 (2005) 31-38
29. Wickmann L., Lüders H., and Dörffel W. 18-FDG-PET-findings in children and adolescents with Hodgkin's disease: retrospective evaluation of the correlation to other imaging procedures in initial staging and to the predictive value of follow up examinations. Klin Padiatr 215 (2003) 146-150
30. Miller E., Metser U., Avrahami G., et al. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr 30 (2006) 689-694
31. Kabickova E., Sumerauer D., Cumlivska E., et al. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease. Eur J Nucl Med Mol Imaging 33 (2006) 1025-1031
32. Furth C., Denecke T., Steffen I., et al. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease. J Pediatr Hematol Oncol 28 (2006) 501-512
33. Mody R.J., Bui C., Hutchinson R.J., Frey K.A., and Shulkin B.L. Comparison of (18) F Flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. Leuk Lymphoma 48 (2007) 699-707
34. Minson S, Aibara R, Shaw P, et al. Utility of PET- CT in staging and early response assessment in adolescent patients with classical Hodgkin's Lymphoma (CHL) - A single centre experience. 2007; [abstract], 7th International Symposium on Hodgkin Lymphoma, Cologne, Germany.
35. Hernandez-Pampaloni M., Takalkar A., Yu J.Q., Zhuang H., and Alavi A. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol 36 (2006) 524-531
36. Carr R., Barrington S.F., Madan B., et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91 (1998) 3340-3346
37. Römer W., Hanauske A.R., Ziegler S., et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 91 (1998) 4464-4471
38. MacManus M.P., Seymour J.F., and Hicks R.J. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging 7 (2007) 10-18
39. Querellou S., Valette F., Bodet-Milin C., et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 85 (2006) 759-767
40. Schot B.W., Zijlstra J.M., Sluiter W.J., et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 109 (2007) 486-491
41. Gallamini A., Hutchings M., Rigacci L., et al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25 (2007) 3746-3752
42. Weihrauch M.R., Re D., Scheidhauer K., et al. Thoracic positron emission tomography using 18F- fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98 (2001) 2930-2934
43. Spaepen K., Stroobants S., Dupont P., et al. Can positron emission tomography with [(18) F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. Br J Haematol 115 (2001) 272-278
44. Guay C., Lépine M., Verreault J., and Bénard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 44 (2003) 1225-1231
45. Schaefer N.G., Taverna C., Strobel K., Wastl C., Kurrer M., and Hany T.F. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy-is biopsy of FDG-avid lesions still needed?. Radiology 244 (2007) 257-262
46. Edeline V., Bonardel G., Brisse H., et al. Prospective study of 18F-FDG PET in pediatric mediastinal lymphoma: a single center experience. Leuk Lymphoma 48 (2007) 823-826
47. Rhodes M.M., Delbeke D., Whitlock J.A., et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 28 (2006) 300-306
48. Meany H.J., Gidvani V.K., and Minniti C.P. Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 48 (2007) 399-402
49. Levine J.M., Weiner M., and Kelly K.M. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol 28 (2006) 711-714
50. Hutchings M., Loft A., Hansen M., Ralfkiaer E., and Specht L. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 24 (2006) 146-150
51. Döbert N., Menzel C., Berner U., et al. Positron emission tomography in patients with Hodgkin's disease: correlation to histopathologic subtypes. Cancer Biother Radiopharm 18 (2003) 565-571
52. Jerusalem G., Beguin Y., Najjar F., et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 12 (2001) 825-830
53. Buchmann I., Reinhardt M., Elsner K., et al. 2-(fluorine-18) fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 91 (2001) 889-899
54. Sattar T., Griffeth L.K., Latifi H.R., Glass J., Munker R., and Lilien D.L. PET imaging today: contribution to the initial staging and prognosis of patients with non-Hodgkin's lymphomas. J La State Med Soc 158 (2006) 193-201
55. Bucerius J., Herkel C., Joe A.Y., et al. F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma. An analysis of 193 patient studies. Nuklearmedizin 45 (2006) 105-110
56. Amthauer H., Furth C., Denecke T., et al. FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up. Klin Padiatr 217 (2005) 327-333
57. Mikhaeel N.G., Hutchings M., Fields P.A., O'Doherty M.J., and Timothy A.R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16 (2005) 1514-1523
58. Kostakoglu L., Goldsmith S.J., Leonard J.P., et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 107 (2006) 2678-2687
59. Zhao J, Qiao W, Wang C, Wang T, Xing Y. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18) F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma. Hematology 2007; Jun 21:1 [Epub ahead of print].
60. Schöder H., Noy A., Gönen M., et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 4643-4651
61. Tatsumi M., Engles J.M., Ishimori T., Nicely O., Cohade C., and Wahl R.L. Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med 45 (2004) 1189-1193
62. Söderlund V., Larsson S.A., and Jacobsson H. Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol. Eur J Nucl Med Mol Imaging 34 (2007) 1018-1022
63. Shankar L.K., Hoffman J.M., Bacharach S., et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47 (2006) 1059-1066
64. Patlak C.S., and Blasberg R.G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 5 (1985) 584-590
65. Hudson M.M., Krasin M.J., and Kaste S.C. PET imaging in pediatric Hodgkin's lymphoma. Pediatr Radiol 34 (2004) 190-198
66. Castellucci P., Nanni C., Farsad M., et al. Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun 26 (2005) 689-694
67. Kaste S.C., Howard S.C., McCarville E.B., Krasin M.J., Kogos P.G., and Hudson M.M. 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin's. Pediatr Radiol 35 (2005) 141-154
68. Jacene H.A., Ishimori T., Engles J.M., Leboulleux S., Stearns V., and Wahl R.L. Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med 47 (2006) 950-956
69. Sugawara Y., Fisher S.J., Zasadny K.R., Kison P.V., Baker L.H., and Wahl R.L. Preclinical and clinical studies of bone marrow uptake of fluorine-1- fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 16 (1998) 173-180
70. Lorenzen J., de Wit M., Buchert R., Igel B., and Bohuslavizki K.H. Granulation tissue: pitfall in therapy control with F-18-FDG PET after chemotherapy. Nuklearmedizin 38 (1999) 333-336
71. Salhab K.F., Baram D., and Bilfinger T.V. Growing PET positive nodule in a patient with histoplasmosis: case report. J Cardiothorac Surg 1 (2006) 23
72. Evans K.D., Tulloss T.A., and Hall N. 18FDG uptake in brown fat: potential for false positives. Radiol Technol 78 (2007) 361-366
73. Ohtsuka T., Nomori H., Watanabe K., et al. False-positive findings on [18F] FDG-PET caused by non-neoplastic cellular elements after neoadjuvant chemoradiotherapy for non-small cell lung cancer. Jpn J Clin Oncol 35 (2005) 271-273
74. Spaepen K., Stroobants S., Dupont P., et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?. Eur J Nucl Med Mol Imaging 30 (2003) 682-688
75. Naumann R., Vaic A., Beuthien-Baumann B., et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 115 (2001) 793-800
76. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25 (2007) 571-578
77. Lee Y.K., Cook G., Flower M.A., et al. Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. Radiother Oncol 73 (2004) 277-283
78. Hutchings M., Loft A., Hansen M., Berthelsen A.K., and Specht L. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 78 (2007) 206-212
79. Thill R., Neuerburg J., Fabry U., et al. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin 36 (1997) 234-239
80. Hernandez-Maraver D., Hernandez-Navarro F., Gomez-Leon N., et al. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. Br J Haematol 135 (2006) 293-302
81. Seam P., Juweid M.E., and Cheson B.D. The role of FDG-PET scans in patients with lymphoma. Blood (2007) 10.1182/blood-2007-06-097238